Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism, a condition in which the thyroid gland produces too much of the hormone thyroxine. It is named after Robert J. Graves, an Irish physician who first described the disorder in 1835. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Symptoms of Graves’ disease can include weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland.
Graves’ disease is an autoimmune disorder in which the body’s immune system mistakenly attacks the thyroid gland. This causes the thyroid gland to produce too much of the hormone thyroxine. Too much thyroxine can lead to a number of symptoms, including weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Graves’ disease is the most common form of hyperthyroidism, and it is estimated to affect approximately 1 in 200 people.
The exact cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Studies have shown that people with Graves’ disease are more likely to have certain genetic variations, which may increase their risk of developing the disorder. Additionally, environmental factors such as stress, smoking, and certain medications may increase the risk of developing Graves’ disease.
Graves’ disease is typically diagnosed based on a physical examination and a review of the patient’s medical history. A doctor may also order blood tests to measure levels of thyroid hormones and antibodies associated with Graves’ disease. An imaging test such as an ultrasound or CT scan may be used to look for an enlarged thyroid gland.
Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. Medications such as antithyroid drugs, beta-blockers, and radioactive iodine can be used to reduce the production of thyroxine. Surgery to remove part or all of the thyroid gland is usually recommended for people with severe symptoms or those who do not respond to medications.
Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism and it is estimated to affect approximately 1 in 200 people. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. It is important for doctors to be aware of the signs and symptoms of Graves’ disease in order to properly diagnose and treat the disorder.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
1.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation